Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

An updated analysis of the ENZAMET trial confirms earlier findings that adding enzalutamide to testosterone suppression provides statistically and clinically meaningful survival improvements in metastatic hormone-sensitive prostate cancer.

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions.

Continuing enzalutamide treatment in combination with docetaxel reduces the risk for progression versus placebo plus docetaxel in men with metastatic castration-resistant prostate cancer that progressed during enzalutamide monotherapy, PRESIDE study data show.

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

The addition of enzalutamide to exemestane may improve the progression-free survival of a subset of patients with HR-positive, HER2-negative, advanced breast cancer, study data suggest.

The phase 3 IMbassador250 trial has failed to show any significant improvement in metastatic castration-resistant prostate cancer outcomes with the addition of atezolizumab to enzalutamide.

The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.

The recommended enzalutamide dose is 160 mg once daily with or without food. --- The Nectin-4-directed antibody–drug conjugate enfortumab vedotin-ejfv has become the first agent of its class to receive FDA approval.

A sequencing strategy that uses abiraterone acetate plus prednisone followed by enzalutamide, rather than the opposite, provides the greatest clinical benefit to patients with newly diagnosed metastatic castration-resistant prostate cancer, researchers report.

Elderly patients with prostate cancer and pre-existing cardiovascular disease have a significantly higher short-term mortality risk following abiraterone acetate or enzalutamide treatment than those without CVD, US study findings indicate.

Supplementing androgen deprivation therapy with enzalutamide delays radiologic progression in men with metastatic castration-sensitive prostate cancer, indicate phase III trial findings presented at the 2019 ASCO Genitourinary Cancers Symposium.

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.

Men positive for androgen receptor splice variant 7 in circulating tumor cells derive little benefit from abiraterone or enzalutamide in the treatment of metastatic castration-resistant prostate cancer, US researchers report.